Edition:
United States

Evotec AG (EVTG.DE)

EVTG.DE on Xetra

20.64EUR
11:35am EDT
Change (% chg)

€1.15 (+5.93%)
Prev Close
€19.49
Open
€20.05
Day's High
€20.68
Day's Low
€19.72
Volume
1,952,749
Avg. Vol
1,092,221
52-wk High
€22.50
52-wk Low
€11.52

Chart for

About

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees,... (more)

Overall

Beta: 0.67
Market Cap(Mil.): €3,039.57
Shares Outstanding(Mil.): 147.55
Dividend: --
Yield (%): --

Financials

  EVTG.DE Industry Sector
P/E (TTM): 90.25 99.04 30.20
EPS (TTM): 0.22 -- --
ROI: 7.54 3.31 12.77
ROE: 9.55 2.31 14.92

German stocks - Factors to watch on June 18

BERLIN/FRANKFURT, June 18 The following are some of the factors that may move German stocks on Monday:

Jun 18 2018

BRIEF-Evotec And Celgene Enter Into Strategic Oncology Partnership

* DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP

May 21 2018

BRIEF-Evotec Says Endometriosis Programme With Bayer Moves To Phase I Development

* DGAP-NEWS: EVOTEC AND BAYER ADVANCE THIRD ENDOMETRIOSIS PROGRAMME INTO PHASE I CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage:

Apr 18 2018

BRIEF-Evotec AG Says ‍Plans Conversion Into European Company​

* SAYS ‍PLANS CONVERSION INTO EUROPEAN COMPANY​ Source text for Eikon: Further company coverage: (Reporting by Frankfurt Newsroom)

Mar 27 2018

Sanofi, Evotec team up for research on infectious diseases treatment

PARIS Sanofi and Evotec said they had started exclusive talks over accelerating research into the treatment of infectious diseases, and added on Thursday that they would form a new open innovation platform in this area, led by Evotec.

Mar 08 2018

Earnings vs. Estimates